Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yoshikatsu Shinbo"'
Autor:
Katsuhiko Akiyama, Ken Morii, Atsushi Kawaguchi, Tetsuro Tamura, Yukihiko Fujii, Hiroaki Hondoh, Manabu Natsumeda, Takafumi Saitoh, Jumpei Homma, Hiroshi Aoki, Hitoshi Takahashi, Naoki Yajima, Masakazu Sano, Yoshihiro Tsukamoto, Ryouske Ogura, Yoshikatsu Shinbo, Ryuya Yamanaka, Naoto Tsuchiya
Publikováno v:
Leukemialymphoma. 58(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94cf339f0e3a51bb80f74fe719775c59
https://pubmed.ncbi.nlm.nih.gov/27397141
https://pubmed.ncbi.nlm.nih.gov/27397141
Autor:
Masakazu Sano, Naoki Yajima, Junpei Homma, Yoshikatsu Shinbo, Akira Hasegawa, Takashi Saitoh, Ryuichi Tanaka, Ryuya Yamanaka, Naoto Tsuchiya, Hideaki E. Takahashi
Publikováno v:
Leukemia & Lymphoma. 48:1429-1433
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95dec0745b0c751b2e52cdba0509ab7c
https://doi.org/10.1080/10428190701370605
https://doi.org/10.1080/10428190701370605
Autor:
Junpei Homma, Ryuya Yamanaka, Masakazu Sano, Naoto Tsuchiya, Kiyoshi Onda, Akira Hasegawa, Ryuichi Tanaka, Yoshikatsu Shinbo, Naoki Yajima
Publikováno v:
Leukemia & Lymphoma. 48:1019-1022
To cite this Article: Yamanaka, Ryuya, Homma, Junpei, Sano, Masakazu, Tsuchiya, Naoto, Yajima, Naoki, Shinbo, Yoshikatsu, Hasegawa, Akira, Onda, Kiyoshi and Tanaka, Ryuichi , 'Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::55441eb820ce14ad0aa185ec5422d4f9
https://doi.org/10.1080/10428190701248009
https://doi.org/10.1080/10428190701248009
Autor:
Naoki Yajima, Ryuichi Tanaka, Masakazu Sano, Jumpei Homma, Hiroaki Hondoh, Tetsuro Tamura, Ken Morii, Yoshikatsu Shinbo, Ryuya Yamanaka, Hideaki E. Takahashi, Naoto Tsuchiya, Kiyoshi Onda
Publikováno v:
Leukemia & Lymphoma. 48:1119-1126
We report the efficacy of salvage therapy with a modified ProMACE-MOPP combined with radiation in patients with primary central nervous system lymphoma (PCNSL). Thirty-two immunocompetent patients were treated with a regimen of pirarubicin, cyclophos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd31c8fe7ed0c89e390b07ea0eaa7e61
https://doi.org/10.1080/10428190701299564
https://doi.org/10.1080/10428190701299564
Autor:
Ken Morii, Hideaki E. Takahashi, Shigekazu Takeuchi, Ryuichi Tanaka, Yoshikatsu Shinbo, Tetsuro Tamura, Hitoshi Takahashi, Ryuya Yamanaka, Hiroaki Hondoh, Kiyoshi Onda
Publikováno v:
Annals of Hematology. 84:447-455
The object of this study was to assess the estimation of 2- and 5-year overall survival and tumor response and the frequency and severity of treatment morbidity with a modified ProMACE-MOPP hybrid protocol in patients with primary CNS lymphoma (PCNSL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75368d2fa5691c0509417eb8fa74945f
https://doi.org/10.1007/s00277-005-1005-9
https://doi.org/10.1007/s00277-005-1005-9